Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 10514660
• 负责人: RAPHAEL E. POLLOCK
• 金额: $ 10.75万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-12 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10514660
• 关键词: Address; Appalachian Region; Attention; Basic Science; Breast; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Research Project; Cancer Survivorship; Catchment Area; Chemoprevention; Clinical Research; Clinical Trials; Colorectal; Community Networks; Community Outreach; Comprehensive Cancer Center; Descriptor; Doctor of Philosophy; Education and Outreach; Endometrial; Engineering; Etiology; FDA approved; Faculty; Fostering; Funding; Growth; Hematopoietic Neoplasms; Human Papilloma Virus Vaccination; Immunooncology; Intervention; Investments; Journals; Leadership; Lesbian Gay Bisexual Transgender Queer; Longevity; Lung; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Manuscripts; Mission; Molecular Biology; Molecular Carcinogenesis; Morbidity - disease rate; Multicultural Education; Obesity; Ohio; Oncology; Patients; Peer Review; Pharmaceutical Preparations; Policies; Population; Population Research; Population Sciences; Prevention; Prostate; Public Health; Publications; Publishing; Research; Resource Sharing; Resources; Rural; Scanning; Scientist; Screening for cancer; Strategic Planning; Therapeutic Trials; Thyroid Gland; Tobacco use; Training; Translating; Translational Research; Underserved Population; Universities; University resources; Vision; anticancer research; cancer genetics; cancer prevention; cancer research center director; clinical development; community engagement; ethnic minority; innovation; leukemia; member; mortality; next generation; outreach; preclinical development; programs; racial and ethnic; recruit; screening; survivorship; translational genomics; translational therapeutics

PROJECT SUMMARY – OVERALL The Ohio State University Comprehensive Cancer Center (OSUCCC) is in its 44th year as an NCI-designated comprehensive cancer center, having received an “exceptional” overall merit descriptor in its last two reviews in 2010 and 2015, and is requesting continued federal support for the next five years. The OSUCCC mission remains to reduce cancer morbidity and mortality through basic, population, translational and clinical research. Through thoughtful strategic planning, attention to the cancer burden in the catchment area (the state of Ohio), effective organizational capabilities and targeted investment, the Director and his Senior Leadership team will enable the OSUCCC to advance collaborative cancer research with local, national and global partners on initiatives of the highest priority to the OSUCCC. The 293 full and introductory members are currently served by 16 full and two developing shared resources and are distributed among our five Research Programs: Cancer Biology (formerly Molecular Biology and Cancer Genetics), Cancer Control, Leukemia Research, Molecular Carcinogenesis and Chemoprevention and Translational Therapeutics. The OSUCCC fosters collaborative basic research and implements strategies that advance and translate early discovery into clinical and population-based research and addresses the needs of our catchment area through research, engagement and outreach, from etiology through prevention, treatment and survivorship regarding the major cancers afflicting our catchment area population. The OSUCCC trains the next generation of cancer-focused scientists and clinicians through new and established programs focused on integrating training for collaborative research efforts. Under the leadership of a new Director, Raphael Pollock, MD, PhD, The OSUCCC supports innovative research efforts within four strategic planning priorities: immuno-oncology, cancer engineering, translational genomics and cancer prevention and survivorship. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth demonstrated by: 1) the recruitment of 108 basic, population, and translational science faculty who are OSUCCC members; 2) the addition of 94,647 ft2 research and administrative space under the full control of the OSUCCC Director; 3) a 16% increase in direct cancer-related funding to $75.4M, with $44.3M coming from the NCI; 4) accrual of 14,996 patients to interventional clinical trials (5,648 accruals to therapeutic trials); 5) increased collaborative and impactful research demonstrated by 3,477 peer-reviewed publications in which 74% of manuscripts are multi-institutional and 85% are collaborative (i.e., inter-, intra-programmatic or multi- institutional); 497 are published in journals with an impact factor >10; 6) the addition of two new shared resources at an institutional investment of $1.3M; and 7) preclinical and clinical development of an FDA approved drug which has changed the treatment for CLL and other blood cancers. With new recruits and strong institutional and philanthropic support in place, the OSUCCC is building upon the momentum and poised in the next five years to take significant steps toward achieving our mission and our broad vision of living in a cancer-free world.

项目总结--总体 俄亥俄州立大学综合癌症中心(OSUCCC)是NCI指定的第44个年头 综合癌症中心，在其最近的两次审查中获得了“特殊的”总体优点描述 2010年和2015年，并正在请求联邦政府在未来五年继续提供支持。OSUCCC任务 通过基础研究、人口研究、转化研究和临床研究来降低癌症发病率和死亡率。 通过深思熟虑的战略规划，关注集水区(俄亥俄州)的癌症负担， 有效的组织能力和有针对性的投资，主任和他的高级领导团队将 使OSUCCC能够推进与当地、国家和全球合作伙伴在以下方面的合作 OSUCCC最优先考虑的举措。293名正式成员和介绍性成员目前由 16个完整的和两个正在开发的共享资源，并在我们的五个研究计划中分发：癌症 生物学(原分子生物学和癌症遗传学)，癌症控制，白血病研究，分子 癌症发生、化学预防和转化性治疗。OSUCCC促进协作基础 研究和实施促进早期发现并将其转化为临床和基于人群的战略 通过研究、参与和外展，从以下方面研究和满足我们集水区的需求 关于困扰我们流域的主要癌症的预防、治疗和生存的病因学 地区人口。OSUCCC通过以下途径培训下一代专注于癌症的科学家和临床医生 新的和已建立的方案侧重于整合协作研究工作的培训。在.之下 在新任主任拉斐尔·波洛克医学博士的领导下，OSUCCC支持创新研究努力 在四个战略规划优先事项内：免疫肿瘤学、癌症工程、翻译基因组学和 癌症预防和生存。自上次CCSG竞争续签以来，OSUCCC已表明 显著增长表现为：1)招聘108名基础科学、人口科学和翻译科学教师 谁是OSUCCC成员；2)在完全控制下增加了94,647平方英尺的研究和行政空间 OSUCCC主任；3)与癌症相关的直接资金增加16%，达到7540万美元，未来将达到4430万美元 来自NCI；4)14,996名患者参加干预性临床试验(5648名患者参加治疗试验)；5) 3477篇同行评议的出版物证明了更多的协作和有影响力的研究，其中74% 85%的手稿是多机构的，85%是协作的(即，方案间、方案内或多机构) 机构)；497以影响因子发表在期刊上&>10；6)增加两个新的共享资源 机构投资130万美元；以及7)FDA批准的药物的临床前和临床开发 这改变了慢性淋巴细胞性白血病和其他血癌的治疗方法。拥有新员工和强大的机构 和慈善支持到位，OSUCCC正在巩固势头，并在未来五年做好准备 为了实现我们的使命和我们生活在一个无癌世界的广阔愿景，我们将在数年内采取重大步骤。